Dry Eye Syndrome – Global Drug Forecast and Market Analysis to 2028

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

• Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is a multifactorial disease of the tears and ocular surface that causes ocular discomfort, visual disturbances, and tear film instability, which can potentially damage the ocular surface. The DES market has had few new therapeutics in the last decade. However, the current treatment landscape is anticipated to witness a dramatic progress with the expected launch of numerous pipeline DES drugs during the forecast period, which will be a significant driver of growth in the 9MM.
• Anticipated to be a lucrative market given that its prevalence is expected to increase during the forecast period as well as a significant need to introduce new therapy options for the indication. Therefore, the trend of strategic deals in DES is expected to increase during the forecast period as more late-stage pipeline products are anticipated to enter the market during this period.
• New pipeline products will help in addressing clinical unmet needs such as need for more therapies. Environmental unmet needs such as need for better diagnostic tools and appropriate clinical trials design are anticipated to be addressed by a combination of the field progressing in terms of disease understanding and product innovations.
Key Questions Answered
• What are the key unmet needs in DES? Will the products in the current pipeline fill these unmet needs?
• When will the late stage pipeline products launch, and how will it affect drug sales and the overall DES market in the 9MM?

Scope

Overview of DES, including epidemiology, pathophysiology, diagnosis, and disease management.

Market Data including annualized DES therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in different patient segments (mild, moderate, severe) forecast from 2018 to 2028.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the DES therapeutics market.

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for DES therapy. The most promising candidates in Phase III development are profiled.

Analysis of the current and future market competition in the global DES therapeutics market: Insightful review of the key industry drivers and barriers. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

The DES market is expected to witness a CAGR of 10.6% from 2018 to 2028, reaching global value of $11.1 billion.

GlobalData anticipates that 16 pipeline drugs will launch over the forecast period and most dominantly in the US market. A small proportion of these products are based on known MOAs such as cyclosporine-based formulations or corticosteroids, while the other products are based on novel MOAs.

While clinical unmet needs such as need for more treatment options are expected to be met by launch of pipeline products in the forecast period, environmental unmet needs such as those for better diagnostic tools are expected to be addressed by a combination of new product launches and improvement in understanding of the disease pathology.

There is also an anticipation that as more pipeline therapies move into the critical stages of late-stage development and pre-approvals, some of these companies with particularly promising therapy for DES may enter into some form of strategic partnerships with other companies in order to maximize the potential of commercial success of these products.

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global DES therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global DES therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Allergan
Aldeyra Therapeutics
Aurinia Pharmaceuticals
Kala Pharmaceuticals
Mitotech
Novaliq
Novartis
Oyster Point Pharma
RegeneRX Biopharmaceuticals
Santen
Senju Pharmaceutical
Sun Pharmaceutical

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 DES: Executive Summary

2.1 Launch of New Pipeline Products and Increasing Prevalence of DES Are Expected to Drive the DES Market Forward

2.2 Pipeline Products with Distinct MOAs Are Likely to Help Companies to Tackle the DES Market

2.3 New Pipeline Products Will Help in Partially Addressing Some Unmet Needs

2.4 Companies Are Undertaking Strategic Deals in Anticipation of Maximizing Sales of DES Products

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Disease Classification

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources Used

5.4.2 Forecast Assumptions and Methods

5.4.3 Forecast Assumptions and Methods – Total and Diagnosed Prevalent Cases of DES

5.4.4 Forecast Assumptions and Methods – Total and Diagnosed Prevalent Cases of DES by Severity

5.5 Epidemiological Forecast for DES (2018–2028)

5.5.1 Diagnosed Prevalent Cases of DES

5.5.2 Age-Specific Diagnosed Prevalent Cases of DES

5.5.3 Sex-Specific Diagnosed Prevalent Cases of DES

5.5.4 Diagnosed Prevalent Cases of DES by Severity

5.5.5 Total Prevalent Cases of DES

5.5.6 Total Prevalent Cases of DES by Severity

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of the Analysis

5.6.3 Strengths of the Analysis

6 Disease Management

6.1 Diagnosis and Treatment Overview

6.1.1 Diagnosis

6.1.2 Treatment Guidelines

6.1.3 Clinical Practice

6.2 US

6.3 5EU

6.4 Japan

6.5 China

6.6 India

7 Competitive Assessment

7.1 Overview

7.1.1 Cyclosporine

7.1.2 LFA-1 Antagonist

7.1.3 Mucin Secretagogue

7.1.4 Corticosteroids

7.1.5 Artificial Tears

7.1.6 Autologous Serum

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 More Treatment Options with Favorable Tolerability Profiles

8.3 Better Diagnostic Tools

8.4 Appropriate Clinical Trial Design

8.5 Simplified Dosing with Cost-Effective Options

9 Pipeline Assessment

9.1 Overview

9.2 Late-Stage Pipeline Products

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Allergan

10.4 Aldeyra Therapeutics

10.5 Aurinia Pharmaceuticals

10.6 Kala Pharmaceuticals

10.7 Mitotech

10.8 Novaliq

10.9 Novartis

10.10 Oyster Point Pharma

10.11 RegeneRX Biopharmaceuticals/ReGenTree

10.12 Santen

10.13 Senju Pharmaceutical

10.14 Sun Pharmaceutical

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers – Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

11.5 China

11.5.1 Forecast

11.5.2 Key Events

11.5.3 Drivers and Barriers

11.6 India

11.6.1 Forecast

11.6.2 Key Events

11.6.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Diagnosed Patients

12.3.3 Percent Drug-Treated Patients

12.3.4 Drugs Included in Each Therapeutic Class

12.3.5 Launch and Patent Expiry Dates

12.3.6 General Pricing Assumptions

12.3.7 Individual Drug Assumptions

12.3.8 Generic Erosion

12.3.9 Pricing of Pipeline Agents

12.4 Primary Research – Key Opinion Leaders Interviewed for This Report

12.4.1 Key Opinion Leaders

12.5 Primary Research – Prescriber Survey

12.6 About the Authors

12.6.1 Analyst

12.6.2 Therapy Area Director

12.6.3 Epidemiologist

12.6.4 Reviewers

12.6.5 Global Director of Therapy Analysis and Epidemiology

12.6.6 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaimer

Table

Table 1: DES: Key Metrics in the 9MM

Table 2: Risk Factors and Comorbidities for DES

Table 3: Diagnostic Tests for DES

Table 4: Popular Validated Questionnaires for DES

Table 5: Treatment Guidelines for DES

Table 6: Country Profile – US

Table 7: Country Profile – 5EU

Table 8: Country Profile – Japan

Table 9: Country Profile – China

Table 10: Country Profile – India

Table 11: Leading Treatments for DES, 2018

Table 12: Comparison of Therapeutic Classes in Development for DES, 2018–2028

Table 13: Allergan’s DES Portfolio Assessment, 2018

Table 14: Aldeyra’s DES Portfolio Assessment, 2018

Table 15: Aurinia’s DES Portfolio Assessment, 2018

Table 16: Kala’s DES Portfolio Assessment, 2018

Table 17: Mitotech’s DES Portfolio Assessment, 2018

Table 18: Novaliq’s DES Portfolio Assessment, 2018

Table 19: Novartis’ DES Portfolio Assessment, 2018

Table 20: Oyster Point Pharma’s DES Portfolio Assessment, 2018

Table 21: RegeneRX / ReGenTree’s DES Portfolio Assessment, 2018

Table 22: Santen’s DES Portfolio Assessment, 2018

Table 23: Senju’s DES Portfolio Assessment, 2018

Table 24: Sun’s DES Portfolio Assessment, 2018

Table 25: DES Market – Global Drivers and Barriers, 2018–2028

Table 26: Key Events Impacting Sales for DES in the US, 2018–2028

Table 27: DES Market – Drivers and Barriers in the US, 2018–2028

Table 28: Key Events Impacting Sales for DES in the 5EU, 2018–2028

Table 29: DES Market – Drivers and Barriers in the 5EU, 2018–2028

Table 30: Key Events Impacting Sales for DES in Japan, 2018–2028

Table 31: DES Market – Global Drivers and Barriers in Japan, 2018–2028

Table 32: Key Events Impacting Sales for DES in China, 2018–2028

Table 33: DES Market – Global Drivers and Barriers in China, 2018–2028

Table 34: DES Market – Global Drivers and Barriers in India, 2018–2028

Table 35: Key Historical and Projected Launch Dates for DES

Table 36: Key Historical and Projected Patent Expiry Dates for DES

Table 37: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figures

Figure 1: Global Sales Forecast by Country for DES in 2018 and 2028

Figure 2: Analysis of the Company Portfolio Gap in DES During the Forecast Period

Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents for DES During the Forecast Period

Figure 4: Vicious Circle of DES

Figure 5: Classification of DES

Figure 6: 9MM, Diagnosed Prevalence of DES, Men and Women, %, Ages ≥18 Years, 2018

Figure 7: 9MM, Total Prevalence of DES, Men and Women, %, Ages ≥18 Years, 2018

Figure 8: 9MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of DES

Figure 9: 9MM, Sources Used and Not Used to Forecast the Total Prevalent Cases of DES

Figure 10: 9MM, Sources Used to Forecast the Severity of Diagnosed Prevalent Cases of DES

Figure 11: 9MM, Sources Used to Forecast the Severity of Total Prevalent Cases of DES

Figure 12: 9MM, Diagnosed Prevalent Cases of DES, N, Both Sexes, Ages ≥18 Years, 2018

Figure 13: 9MM, Diagnosed Prevalent Cases of DES by Age, N, Both Sexes, 2018

Figure 14: 9MM, Diagnosed Prevalent Cases of DES by Sex, N, Ages ≥18 Years, 2018

Figure 15: 9MM, Diagnosed Prevalent Cases of DES by Severity, N, Ages ≥18 Years, 2018

Figure 16: 9MM, Total Prevalent Cases of DES, N, Both Sexes, Ages ≥18 Years, 2018

Figure 17: 9MM, Total Prevalent Cases of DES by Severity, N, Ages ≥18 Years, 2018

Figure 18: Unmet Needs and Opportunities in DES

Figure 19: Products in Clinical Development for DES, 2018

Figure 20: Key Phase IIb/III Trials for the Promising Pipeline Agents that GlobalData Expects be Licensed for DES in the 9MM During the Forecast Period

Figure 21: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of DES During the Forecast Period

Figure 22: Analysis of the Company Portfolio Gap in DES During the Forecast Period

Figure 23: Number of Deals in DES Market in the 9MM in Prior Years (2005–2019)

Figure 24: Global (9MM) Sales Forecast by Country for DES in 2018 and 2028

Figure 25: Sales Forecast by Drug Class for DES in the US, 2018 and 2028

Figure 26: Sales Forecast by Class for DES in the 5EU in 2018 and 2028

Figure 27: Sales Forecast by Class for DES in Japan in 2018 and 2028

Figure 28: Sales Forecast by Class for DES in China in 2018 and 2028

Figure 29: Sales Forecast by Class for DES in India in 2018 and 2028

Frequently asked questions

Dry Eye Syndrome – Global Drug Forecast and Market Analysis to 2028 thematic reports
Currency USD
$10,995

Can be used by individual purchaser only

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Dry Eye Syndrome – Global Drug Forecast and Market Analysis to 2028 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Dry Eye Syndrome – Global Drug Forecast and Market Analysis to 2028 in real time.

  • Access a live Dry Eye Syndrome – Global Drug Forecast and Market Analysis to 2028 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.